-
EP4011881
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4011881
| EP4011881 - CRYSTALLINE FORM OF ATR INHIBITOR AND USE THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 13.05.2022 Database last updated on 14.06.2024 | |
| Former | The international publication has been made Status updated on 12.02.2021 | Most recent event Tooltip | 23.01.2024 | The date on which the examining division becomes responsible, has been established | 23.01.2024 | Amendment by applicant | Applicant(s) | For all designated states Wuxi Biocity Biopharmaceutics Co., Ltd. Room 315, Meiliang Road No.88 Mashan, Binhu District Wuxi, Jiangsu 214000 / CN | [2022/24] | Inventor(s) | 01 /
WANG, Jian 288 Futezhong Road, Pudong New Area Shanghai 200131 / CN | 02 /
YAO, Ting 288 Futezhong Road, Pudong New Area Shanghai 200131 / CN | 03 /
QIAN, Wenyuan 288 Futezhong Road, Pudong New Area Shanghai 200131 / CN | 04 /
LI, Jian 288 Futezhong Road, Pudong New Area Shanghai 200131 / CN | 05 /
CHEN, Shuhui 288 Futezhong Road, Pudong New Area Shanghai 200131 / CN | [2022/24] | Representative(s) | Müller, Christian Stefan Gerd ZSP Patentanwälte PartG mbB Hansastraße 32 80686 München / DE | [2022/24] | Application number, filing date | 20851028.9 | 06.08.2020 | [2022/24] | WO2020CN107474 | Priority number, date | CN201910722102 | 06.08.2019 Original published format: CN201910722102 | [2022/24] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021023272 | Date: | 11.02.2021 | Language: | ZH | [2021/06] | Type: | A1 Application with search report | No.: | EP4011881 | Date: | 15.06.2022 | Language: | EN | [2022/24] | Search report(s) | International search report - published on: | CN | 11.02.2021 | (Supplementary) European search report - dispatched on: | EP | 06.07.2023 | Classification | IPC: | A61P35/00, A61K31/5377, C07D413/14 | [2023/32] | CPC: |
A61P35/00 (EP,IL);
A61K31/437 (IL);
C07D413/14 (EP,US);
C07D471/04 (IL);
C07B2200/13 (US)
|
| Former IPC [2022/24] | C07D471/04, A61P35/00, A61K31/437 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/24] | Title | German: | KRISTALLINE FORM VON ATR-INHIBITOREN UND DEREN VERWENDUNG | [2022/24] | English: | CRYSTALLINE FORM OF ATR INHIBITOR AND USE THEREOF | [2022/24] | French: | FORME CRISTALLINE D'UN INHIBITEUR D'ATR ET SON UTILISATION | [2022/24] | Entry into regional phase | 27.01.2022 | Translation filed | 27.01.2022 | National basic fee paid | 27.01.2022 | Search fee paid | 27.01.2022 | Designation fee(s) paid | 27.01.2022 | Examination fee paid | Examination procedure | 27.01.2022 | Examination requested [2022/24] | 18.01.2024 | Amendment by applicant (claims and/or description) | 18.01.2024 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 25.08.2022 | Renewal fee patent year 03 | 21.08.2023 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2011154737 (ASTRAZENECA AB [SE], et al) [A] 1-15* claims 1, 9-12 *; | [A]WO2019036641 (UNIV TEXAS [US], et al) [A] 1-15 * claims 1, 20-22 *; | [E]EP3753937 (SHIJIAZHUANG SAGACITY NEW DRUG DEV COMPANY LTD [CN]) [E] 1-15 * paragraph [0345]; compound WX42 * |